Compare BSVN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSVN | FULC |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.1M | 467.8M |
| IPO Year | 2018 | 2019 |
| Metric | BSVN | FULC |
|---|---|---|
| Price | $43.72 | $6.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $53.67 | $16.38 |
| AVG Volume (30 Days) | 6.2K | ★ 538.1K |
| Earning Date | 04-14-2026 | 04-27-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.05 | N/A |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $34.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.91 | $5.88 |
| 52 Week High | $50.10 | $15.74 |
| Indicator | BSVN | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | 42.50 |
| Support Level | $42.02 | $6.36 |
| Resistance Level | $45.58 | $7.09 |
| Average True Range (ATR) | 0.73 | 0.38 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 100.00 | 42.59 |
Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.